中证报中证网讯(王珞)8月15日晚间，天士力（600535）发布的中报显示，公司上半年实现营业收入 42.88亿元，实现归属于上市公司股东的净利润7.75亿元，同比增长16.97%。 安神滴丸申报生产获得受理，安体威颗粒III期、芪参益气滴丸治疗慢性心力衰竭II期完成全部受试者出 组，正在开展数据统计；青术颗粒III期、芪参益气滴丸治疗糖尿病肾脏疾病II期完成全部受试者出组， 正在进行数据清理；三黄睛视明丸启动III期临床；养血清脑丸治疗轻中度阿尔茨海默病II期临床完成入 组，持续开展临床观察。 另外，普佑克(治疗急性缺血性脑卒中)完成CDE审评会。普佑克适应症从急性ST段抬高型心肌梗死(心 梗)治疗拓展至急性缺血性脑卒中(脑梗)治疗，IIIc期研究充分证明了普佑克的有效性和安全性优势，结 果发表于《Lancet Neurology》(IF：46.5)，并于世界卒中大会(WSC)做前沿报告。 华泰证券发布研报指出，天士力中成药领域III期、II期项目预计2025年起陆续上市，丰富的在研管线有 望接力公司未来的业绩成长。 天士力表示，公司秉承"没有围墙的研究院"理念，加强对外合作，全面整合先进技术资源。公司拥有 ...

Core Insights - The article highlights the rapid growth of the ophthalmic drug market in China, with Kanghong Pharmaceutical's product "Langmu" breaking the monopoly of imported drugs and achieving significant sales [1][4][5] - Kanghong Pharmaceutical has established itself as a leader in the innovative drug sector, focusing on ophthalmology, mental health, and oncology, with a strong emphasis on innovation and quality [3][7][12] Company Performance - In 2024, Kanghong Pharmaceutical's biopharmaceutical business revenue reached 2.343 billion yuan, a year-on-year increase of 20.98%, accounting for 52.61% of total revenue [1] - The sales of Kanghong's product, Kangbaxip, reached 500 million yuan in 2023, capturing 36% of the market share [1] - The company has maintained a consistent growth trajectory for Kangbaxip over the past 11 years, with over 2.5 million injections administered [1][5] Market Dynamics - The global ophthalmic drug market is projected to reach $83.477 billion by 2031, with a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031 [3] - China has over 40 million patients with retinal diseases, with more than 3 million new patients added annually, indicating a significant market opportunity [4][8] Innovation and R&D - Kanghong Pharmaceutical has a comprehensive R&D strategy, with 21 marketed drugs, 10 of which are exclusive and 17 included in the national medical insurance directory [3][12] - The company is actively developing gene therapy and antibody drugs, with two ophthalmic products in clinical trials aimed at reducing injection frequency for patients [9][10] Production Capacity - Kanghong is investing in building production capabilities for gene therapy drugs, establishing a full-chain capability from R&D to commercialization [12][13] - The company has constructed GMP-compliant production bases in Beijing and Chengdu, enhancing its manufacturing capabilities for biopharmaceuticals [13]